Biopharmaceutical company focused on developing therapies for sleep and central nervous system disorders.
Harmony Biosciences Holdings, Inc. is a pharmaceutical company at the forefront of developing and bringing to market therapies for individuals suffering from rare neurological disorders in the United States. Central to its portfolio is WAKIX, an innovative medication designed specifically for adult patients with narcolepsy to manage excessive daytime sleepiness effectively. This product represents a significant advancement in addressing a challenging symptom of this disorder.
Formerly known as Harmony Biosciences II, Inc., the company rebranded to Harmony Biosciences Holdings, Inc. in February 2020, reflecting its commitment to advancing neurological therapies. Established in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company has rapidly positioned itself as a leader in the treatment of rare neurological conditions.
Harmony Biosciences Holdings, Inc. distinguishes itself through a dedicated focus on improving the lives of patients with narcolepsy and other rare disorders. By leveraging its expertise and resources, the company aims to continue developing and commercializing innovative treatments that address unmet medical needs in the neurological field.
With a robust pipeline and a patient-centered approach, Harmony Biosciences Holdings, Inc. is poised to expand its impact in the pharmaceutical industry, driven by a commitment to enhancing the quality of life for individuals affected by rare neurological disorders.